CHE Chemed (CHE) Insider Trading, Ownership & Congress Trades
Healthcare Services · Services-home health care services · CIK 0000019584
Form 144 · 5
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
280
13F, latest reported quarter
Conversions, 180 days
5
Codes C/M, not in net · $12.5M priced
What the filings say about CHE
Insiders, 180 days
-$6.5M net sold
5 sellers · 0% of sales under a 10b5-1 plan
Congress, 1 year
No trades
Last one: purchase, 2025-06-24
Planned sales (Form 144), 90 days
$4.3M
5 notices
Chemed insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, CHEMED CORP insiders sold a net $6.5M of stock across 95 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- 33 earlier Form 4 trades (code P or S) here by this insider (33 sales), the last on Sep 18, 2026.
- The trade is 3.0% of the 66,418 shares held after it.
- No other insider sold within 30 days.
- 280 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: president and CEO MCNAMARA KEVIN J sold about $1.0M of CHE on Sep 28, 2026; 280 funds added in the latest 13F quarter.Context
- 32 earlier Form 4 trades (code P or S) here by this insider (32 sales), the last on Aug 21, 2026.
- The trade is 2.9% of the 68,418 shares held after it.
- 1 other insider sold within 30 days.
- 280 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: president and CEO MCNAMARA KEVIN J sold about $1.0M of CHE on Sep 18, 2026; 1 other insider sold within 30 days and 280 funds added in the latest 13F quarter.Context
- 31 earlier Form 4 trades (code P or S) here by this insider (31 sales), the last on Aug 3, 2026.
- The trade is 2.8% of the 70,418 shares held after it.
- 2 other insiders sold within 30 days.
- 280 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: president and CEO MCNAMARA KEVIN J sold about $1.1M of CHE on Aug 21, 2026; 2 other insiders sold within 30 days and 280 funds added in the latest 13F quarter.Context
- 12 earlier Form 4 trades (code P or S) here by this insider (12 sales), the last on May 16, 2025.
- The trade is 7.2% of the 13,912 shares held after it.
- 2 other insiders sold within 30 days.
- 280 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: executive vice president LEE SPENCER S sold about $541.0K of CHE on Aug 21, 2026; 2 other insiders sold within 30 days and 280 funds added in the latest 13F quarter.Context
- 30 earlier Form 4 trades (code P or S) here by this insider (30 sales), the last on May 1, 2026.
- The trade is 2.8% of the 70,418 shares held after it.
- 2 other insiders sold within 30 days.
- 280 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: president and CEO MCNAMARA KEVIN J sold about $1.1M of CHE on Aug 3, 2026; 2 other insiders sold within 30 days and 280 funds added in the latest 13F quarter.95 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net -$6.5M over 180 days
-$4.8M over 90 days
below 59% of Healthcare Services
Congress
no House purchase disclosed in the last 12 months
Funds
280 funds bought in last quarter
more than 85% of Healthcare Services
Revenue
+4.1% year over year
below 70% of Healthcare Services
Margin
10.5% net margin
more than 91% of Healthcare Services
Buybacks
$287.5M repurchased, FY to 2026-06-30
more than 81% of Healthcare Services
Short interest
5.8% of the float short (float per yahoo 2026-10-27) · 4.9 days to cover · settled 2026-10-15
more than 67% of Healthcare Services
What changed in the last 30 days
Sep 30president and CEO MCNAMARA KEVIN J sold $1.0M (Sep 28)
Watch CHE
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+18.3%12M
Insider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns CHE: institutional holders (13F)
13F holdings, latest reported quarter
1,484,282 sh
$691.3M
972,474 sh
$446.2M
787,068 sh
$366.6M
604,420 sh
$281.5M
444,716 sh
$207.1M
Congress trades in CHE
STOCK Act disclosures, US House only, filed up to 45 days after the trade
Bought 2025-06-24 · disclosed 50 days later
$1,001 - $15,000
Sold 2025-03-06 · disclosed 39 days later
$1,001 - $15,000
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
CHE planned insider sales (Form 144)
Notice of intent to sell, filed before any sale
Kevin McNamara
Filed 2026-09-28
$1.1M
MCNAMARA KEVIN J
Filed 2026-09-24
$998.0K
Kevin J McNamara
Filed 2026-08-21
$1.1M
Kevin J McNamara
Filed 2026-08-03
$1.1M
Patrick P. Grace
Filed 2026-07-31
$119.3K
CHE mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
AMERICAN GROWTH FUND Series One
$1.1M position · as of 2026-07-31
4.8%
Bahl & Gaynor Small Cap Dividend ETF
$7.3M position · as of 2026-06-30
4.8%
FAM SMALL CAP FUND
$12.8M position · as of 2026-06-30
4.1%
Formidable Fortress ETF
$598.0K position · as of 2026-06-30
2.8%
LONE PEAK VALUE FUND
$4.0M position · as of 2026-06-30
2.3%
AMG River Road Small Cap Value Fund
$22.4M position · as of 2026-07-31
2.2%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Executive pay vs shareholder return
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$12.9M
$4.1M
$3.4M
-18%
+82%
2024
$12.8M
$6.0M
$3.6M
+22%
+90%
2023
$12.6M
$19.2M
$3.7M
+35%
+51%
2022
$11.6M
$10.1M
$3.9M
+17%
+26%
2021
$11.7M
$13.3M
$3.8M
+21%
+28%
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $6.5M sold by insiders over 180 days, 280 funds added last quarter, $4.3M in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
CHE financials
Revenue growth
+4.1%
XBRL, annual
Net margin
10.5%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$2.6B
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM CHE
| FY Dec 2025 | $2.5B |
| FY Dec 2024 | $2.4B |
| FY Dec 2023 | $2.3B |
| FY Dec 2022 | $2.1B |
| FY Dec 2021 | $2.1B |
| Jun 2026 | $673.3M |
| Mar 2026 | $657.5M |
| Dec 2025 | $639.3M |
| Sep 2025 | $624.9M |
| Jun 2025 | $618.8M |
| Mar 2025 | $646.9M |
| Dec 2024 | $640.0M |
| Sep 2024 | $606.2M |
At each fiscal year end
Single quarter
Net margin, TTM
+0.4%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM CHE
| FY Dec 2025 | +0.0% |
| FY Dec 2024 | +0.0% |
| FY Dec 2023 | +0.0% |
| FY Dec 2022 | +0.0% |
| FY Dec 2021 | +0.0% |
| Jun 2026 | +10.1% |
| Mar 2026 | +10.1% |
| Dec 2025 | -29.4% |
| Sep 2025 | +10.3% |
| Jun 2025 | +8.5% |
| Mar 2025 | +11.1% |
| Dec 2024 | -33.0% |
| Sep 2024 | +12.5% |
At each fiscal year end
Single quarter
Free cash flow, TTM
$323.5M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM CHE
| FY Dec 2025 | $325.3M |
| FY Dec 2024 | n/a |
| FY Dec 2023 | $273.4M |
| FY Dec 2022 | $252.6M |
| FY Dec 2021 | $249.9M |
| Jun 2026 | $69.3M |
| Mar 2026 | $71.1M |
| Dec 2025 | $117.2M |
| Sep 2025 | $65.9M |
| Jun 2025 | $122.8M |
| Mar 2025 | $19.5M |
| Dec 2024 | $152.2M |
| Sep 2024 | $71.9M |
At each fiscal year end
Single quarter
Debt to equity
0.17x
long-term 2026-06-30 plus current 2023-03-31 (39 months older than the period end); equity 2026-06-30
Debt to equity CHE
| FY Dec 2025 | 0.02x |
| FY Dec 2024 | 0.02x |
| FY Dec 2023 | 0.02x |
| FY Dec 2022 | 0.12x |
| FY Dec 2021 | 0.31x |
| Jun 2026 | 0.17x |
| Mar 2026 | 0.11x |
| Dec 2025 | 0.02x |
| Sep 2025 | 0.02x |
| Jun 2025 | 0.02x |
| Mar 2025 | 0.02x |
| Dec 2024 | 0.02x |
| Sep 2024 | 0.02x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
2.69x
TTM operating cash flow over long-term 2026-06-30 plus current 2023-03-31 (39 months older than the period end)
Cash flow to debt CHE
| FY Dec 2025 | 18.27x |
| FY Dec 2024 | 19.65x |
| FY Dec 2023 | 15.54x |
| FY Dec 2022 | 3.18x |
| FY Dec 2021 | 1.58x |
| Jun 2026 | 2.69x |
| Mar 2026 | 4.61x |
| Dec 2025 | 18.27x |
| Sep 2025 | 19.75x |
| Jun 2025 | 20.08x |
| Mar 2025 | 17.21x |
| Dec 2024 | 19.65x |
| Sep 2024 | 17.00x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
+1.0%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity CHE
| FY Dec 2025 | +0.0% |
| FY Dec 2024 | +0.0% |
| FY Dec 2023 | +0.0% |
| FY Dec 2022 | +0.0% |
| FY Dec 2021 | +0.0% |
| Jun 2026 | +1.0% |
| Mar 2026 | -0.5% |
| Dec 2025 | +0.0% |
| Sep 2025 | -2.0% |
| Jun 2025 | -0.9% |
| Mar 2025 | +0.6% |
| Dec 2024 | +0.0% |
| Sep 2024 | +2.6% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
+0.6%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets CHE
| FY Dec 2025 | +0.0% |
| FY Dec 2024 | +0.0% |
| FY Dec 2023 | +0.0% |
| FY Dec 2022 | +0.0% |
| FY Dec 2021 | +0.0% |
| Jun 2026 | +0.6% |
| Mar 2026 | -0.3% |
| Dec 2025 | +0.0% |
| Sep 2025 | -1.3% |
| Jun 2025 | -0.7% |
| Mar 2025 | +0.4% |
| Dec 2024 | +0.0% |
| Sep 2024 | +1.8% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
+25.6%
operating income after a 25.5% effective tax rate, over long-term 2026-06-30 plus current 2023-03-31 (39 months older than the period end) plus average of 2025-06-30 and 2026-06-30 minus cash
Return on invested capital CHE
| FY Dec 2025 | +26.7% |
| FY Dec 2024 | +30.3% |
| FY Dec 2023 | +32.9% |
| FY Dec 2022 | +34.4% |
| FY Dec 2021 | +30.6% |
| Jun 2026 | +25.6% |
| Mar 2026 | +24.0% |
| Dec 2025 | +26.7% |
| Sep 2025 | +26.6% |
| Jun 2025 | +28.0% |
| Mar 2025 | +30.4% |
| Dec 2024 | +30.3% |
| Sep 2024 | +29.5% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
+25.7%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed CHE
| FY Dec 2025 | +25.7% |
| FY Dec 2024 | +26.8% |
| FY Dec 2023 | +27.2% |
| FY Dec 2022 | +31.4% |
| FY Dec 2021 | +31.5% |
| Jun 2026 | +25.7% |
| Mar 2026 | +24.8% |
| Dec 2025 | +25.7% |
| Sep 2025 | +24.8% |
| Jun 2025 | +25.2% |
| Mar 2025 | +27.0% |
| Dec 2024 | +26.8% |
| Sep 2024 | +26.3% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
25.80x
close 2026-10-26 over four quarters of diluted EPS, 2025-07-01 to 2026-06-30
P/E, trailing CHE
| FY Dec 2025 | 23.33x |
| FY Dec 2024 | 26.62x |
| FY Dec 2023 | 32.61x |
| FY Dec 2022 | 30.90x |
| FY Dec 2021 | 31.38x |
| Jun 2026 | 23.43x |
| Mar 2026 | 20.62x |
| Dec 2025 | 23.33x |
| Sep 2025 | 23.69x |
| Jun 2025 | 25.05x |
| Mar 2025 | 29.99x |
| Dec 2024 | 26.62x |
| Sep 2024 | 30.35x |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$6.8B
market value at close 2026-10-26 on 2026-06-30 shares, plus long-term 2026-06-30 plus current 2023-03-31 (39 months older than the period end), minus cash 2026-06-30
Enterprise value CHE
| FY Dec 2025 | $6.0B |
| FY Dec 2024 | $7.8B |
| FY Dec 2023 | $8.6B |
| FY Dec 2022 | $7.6B |
| FY Dec 2021 | $8.3B |
| Jun 2026 | $6.2B |
| Mar 2026 | $5.1B |
| Dec 2025 | $6.0B |
| Sep 2025 | $6.2B |
| Jun 2025 | $6.9B |
| Mar 2025 | $8.8B |
| Dec 2024 | $7.8B |
| Sep 2024 | $8.8B |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
+4.8%
TTM free cash flow over market value at close 2026-10-26
FCF yield CHE
| FY Dec 2025 | +5.4% |
| FY Dec 2024 | n/a |
| FY Dec 2023 | +3.1% |
| FY Dec 2022 | +3.3% |
| FY Dec 2021 | +3.1% |
| Jun 2026 | +5.3% |
| Mar 2026 | +7.5% |
| Dec 2025 | +5.4% |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | +2.5% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
11.40x
P/E over trailing EPS growth of 2%: four quarters to 2026-06-30 against the four to 2025-06-30
PEG, trailing CHE
| FY Dec 2025 | n/a |
| FY Dec 2024 | 2.42x |
| FY Dec 2023 | 3.82x |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | 10.35x |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | 2.89x |
| Dec 2024 | 2.42x |
| Sep 2024 | 1.34x |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $2.5B | $2.4B | $2.3B | $2.1B |
| Operating income | $338.2M | $366.5M | $340.6M | $343.5M |
| Net income | $265.2K | $302.0K | $272.5K | $249.6K |
| EPS (diluted) | n/a | n/a | n/a | n/a |
| Operating cash flow | $388.3M | $417.5M | $330.3M | $309.9M |
| Cash | $74.5M | $178.3M | $264.0M | $74.1M |
| Long-term debt | n/a | n/a | n/a | $92.5M |
| Buybacks | $431.5M | $361.4M | $67.7M | $114.5M |
| Dividends paid | $31.7M | $27.1M | $23.5M | $22.0M |
SEC XBRL, fiscal years, as known on 2026-10-28
CHE Stock Sonar score 6/7 axes
Find similar shapesCompareCHE ranks highest on institutional and government (85th percentile) and financial health (76th), and lowest on insider conviction (17th), among Healthcare Services peers.
6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
CHE filings, in plain words
Are Chemed insiders buying or selling CHE?
In the 180 days to 2026-10-28, Chemed insiders were net sellers, a net $6.5M across purchases and sales reported on Form 4, by 5 sellers.
Have members of Congress traded CHE?
Yes, but not in the year to 2026-10-28; the latest on record is a purchase by Lisa McClain dated 2025-06-24.
Are there planned insider sales of CHE?
Yes. 5 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-28, covering $4.3M of stock; the latest, by Kevin McNamara, was filed 2026-09-28.
Read the full summary
In the 180 days to 2026-10-28, Chemed insiders were net sellers of CHE, a net $6.5M across purchases and sales reported on Form 4 by 5 sellers. None of the 10 insider sales was flagged as made under a Rule 10b5-1 plan. Members of Congress have disclosed trades in CHE, none in the last year; the latest on record is a purchase by Lisa McClain dated 2025-06-24. Insiders filed 5 Form 144 notices of intent to sell in the 90 days to 2026-10-28, covering $4.3M of stock. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
